Abbott (NYSE:ABT) announced today that its next-generation FreeStyle Libre 2 iCGM is now available to Medicare patients.
The integrated continuous glucose monitoring (iCGM) system met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS), making it accessible to all Medicare patients with diabetes who meet the eligibility criteria, according to a news release.
Abbott Park, Ill.-based Abbott’s FreeStyle Libre 2 includes a sensor worn on the back of the upper arm for up to 14 days, using a handheld reader over the sensor to provide real-time glucose readings, trend arrows and eight-hour history to help healthcare providers and users make informed treatment decisions.
The system also includes real-time alarms and minute-by-minute glucose measurements, while Abbott touts it as the longest-lasting self-applied iCGM sensor currently available, eliminating the need for fingersticks and costing a third of the price of other CGM systems.
“Abbott designed the FreeStyle Libre portfolio for performance, access and affordability to make it broadly available to people with diabetes who need it,” Abbott senior VP of diabetes care Jared Watkin said in the release. “By securing reimbursement, Abbott is making sure our latest life-changing technology can get to everyone who needs it, whether they’re children, adults or seniors eligible for Medicare.”
